<DOC>
	<DOCNO>NCT00406211</DOCNO>
	<brief_summary>Follow-up evaluate immunogenicity safety three production lot GSK Biologicals ' MMRV vaccine give two-dose schedule healthy child second year life , compare separate administration GSK Biologicals ' measles-mumps-rubella ( MMR ) vaccine ( Priorix® ) varicella vaccine ( Varilrix® ) Germany &amp; Austria . Blood sample collect three time point follow-up period ( Year 1 , 2 &amp; 3 ) . No new subject enrol follow-up phase study .</brief_summary>
	<brief_title>Long-term Follow-up Immunogenicity &amp; Safety Measles-Mumps-Rubella-Varicella ( MMRV ) Combined Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Written inform consent parents/guardians child participate longterm followup . Subjects must receive complete vaccination course accord group allocation ( i.e . subject must receive either two dos MMRV combine vaccine , two dos Priorix vaccine one dose Varilrix vaccine separate injection primary vaccination study . Subjects age 12 18 month age time first vaccination primary study . Subjects must receive additional dose measles , mumps , rubella varicella contain vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rubella</keyword>
	<keyword>Varicella</keyword>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Germany</keyword>
	<keyword>Austria</keyword>
</DOC>